Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.11
GNC's Cash to Debt is ranked higher than
55% of the 558 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.49 vs. GNC: 0.11 )
GNC' s 10-Year Cash to Debt Range
Min: 0.06   Max: No Debt
Current: 0.11

Equity to Asset 0.28
GNC's Equity to Asset is ranked higher than
58% of the 558 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.42 vs. GNC: 0.28 )
GNC' s 10-Year Equity to Asset Range
Min: 0.24   Max: 0.42
Current: 0.28

0.24
0.42
Interest Coverage 10.74
GNC's Interest Coverage is ranked higher than
67% of the 427 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 13.31 vs. GNC: 10.74 )
GNC' s 10-Year Interest Coverage Range
Min: 2.02   Max: 10.74
Current: 10.74

2.02
10.74
F-Score: 6
Z-Score: 3.40
M-Score: -2.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 16.68
GNC's Operating margin (%) is ranked higher than
98% of the 561 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.50 vs. GNC: 16.68 )
GNC' s 10-Year Operating margin (%) Range
Min: 10.24   Max: 17.61
Current: 16.68

10.24
17.61
Net-margin (%) 9.60
GNC's Net-margin (%) is ranked higher than
97% of the 561 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.26 vs. GNC: 9.60 )
GNC' s 10-Year Net-margin (%) Range
Min: 3.3   Max: 10.08
Current: 9.6

3.3
10.08
ROE (%) 32.29
GNC's ROE (%) is ranked higher than
97% of the 551 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 10.22 vs. GNC: 32.29 )
GNC' s 10-Year ROE (%) Range
Min: 10.03   Max: 31.22
Current: 32.29

10.03
31.22
ROA (%) 9.40
GNC's ROA (%) is ranked higher than
93% of the 563 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.09 vs. GNC: 9.40 )
GNC' s 10-Year ROA (%) Range
Min: 3.01   Max: 10.02
Current: 9.4

3.01
10.02
ROC (Joel Greenblatt) (%) 62.09
GNC's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 562 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.27 vs. GNC: 62.09 )
GNC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 41.63   Max: 73.51
Current: 62.09

41.63
73.51
Revenue Growth (3Y)(%) 9.60
GNC's Revenue Growth (3Y)(%) is ranked higher than
87% of the 494 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.70 vs. GNC: 9.60 )
GNC' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 9.6
Current: 9.6

0
9.6
EBITDA Growth (3Y)(%) 20.90
GNC's EBITDA Growth (3Y)(%) is ranked higher than
93% of the 462 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.90 vs. GNC: 20.90 )
GNC' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 20.9
Current: 20.9

0
20.9
EPS Growth (3Y)(%) 47.40
GNC's EPS Growth (3Y)(%) is ranked higher than
97% of the 424 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.20 vs. GNC: 47.40 )
GNC' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 58.1
Current: 47.4

0
58.1
» GNC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

GNC Guru Trades in Q4 2013

Paul Tudor Jones 27,563 sh (New)
Caxton Associates 6,344 sh (New)
Joel Greenblatt 155,608 sh (+216.08%)
Columbia Wanger 2,569,200 sh (unchged)
John Keeley 209,030 sh (-0.26%)
Mario Gabelli 10,500 sh (-7.89%)
RS Investment Management 695,403 sh (-13.57%)
Jim Simons 122,500 sh (-61.73%)
Steven Cohen 321,936 sh (-88.04%)
» More
Q1 2014

GNC Guru Trades in Q1 2014

Joel Greenblatt 364,031 sh (+133.94%)
RS Investment Management 1,243,648 sh (+78.84%)
Paul Tudor Jones 39,787 sh (+44.35%)
Mario Gabelli 13,470 sh (+28.29%)
John Keeley 218,460 sh (+4.51%)
Caxton Associates Sold Out
Columbia Wanger 2,568,400 sh (-0.03%)
Jim Simons 98,700 sh (-19.43%)
Steven Cohen 4,955 sh (-98.46%)
» More
Q2 2014

GNC Guru Trades in Q2 2014

Louis Moore Bacon 30,000 sh (New)
Richard Snow 15,400 sh (New)
Jim Simons 343,000 sh (+247.52%)
Joel Greenblatt 861,384 sh (+136.62%)
Mario Gabelli 16,205 sh (+20.3%)
RS Investment Management 1,275,693 sh (+2.58%)
John Keeley Sold Out
Columbia Wanger 1,640,600 sh (-36.12%)
Paul Tudor Jones 10,394 sh (-73.88%)
» More
Q3 2014

GNC Guru Trades in Q3 2014

Private Capital 420,786 sh (New)
Paul Tudor Jones 21,913 sh (+110.82%)
Richard Snow 21,900 sh (+42.21%)
Jim Simons Sold Out
Louis Moore Bacon Sold Out
RS Investment Management 1,205,573 sh (-5.5%)
Mario Gabelli 14,420 sh (-11.02%)
Joel Greenblatt 550,896 sh (-36.05%)
Columbia Wanger 969,600 sh (-40.9%)
» More
» Details

Insider Trades

Latest Guru Trades with GNC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Private Capital 2014-09-30 New Buy1.9%$32.38 - $41.02 $ 45.0424%420786
Joel Greenblatt 2014-09-30 Reduce -36.05%0.13%$32.38 - $41.02 $ 45.0424%550896
Richard Snow 2014-09-30 Add 42.21%0.01%$32.38 - $41.02 $ 45.0424%21900
Joel Greenblatt 2014-06-30 Add 136.62%0.21%$33.86 - $46.86 $ 45.0413%861384
John Keeley 2014-06-30 Sold Out 0.17%$33.86 - $46.86 $ 45.0413%0
Richard Snow 2014-06-30 New Buy0.02%$33.86 - $46.86 $ 45.0413%15400
Mario Gabelli 2014-06-30 Add 20.3%$33.86 - $46.86 $ 45.0413%16205
Joel Greenblatt 2014-03-31 Add 133.94%0.14%$43.2 - $58.45 $ 45.04-10%364031
Mario Gabelli 2014-03-31 Add 28.29%$43.2 - $58.45 $ 45.04-10%13470
Joel Greenblatt 2013-12-31 Add 216.08%0.15%$53 - $60.56 $ 45.04-22%155608
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about GNC Holdings Inc

Private Capital Reduces Holdings in Healthcare Stocks
Gregg Powers, who became CEO of Private Capital (Trades, Portfolio) Management when founder Bruce Sherman retired five years ago, began his career as a healthcare analyst at Raymond James Financial. Consequently, it should come as no surprise that healthcare stocks represent a little more than one-fifth of the content of the firm’s portfolio. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 16.50
GNC's P/E(ttm) is ranked higher than
86% of the 589 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 22.50 vs. GNC: 16.50 )
GNC' s 10-Year P/E(ttm) Range
Min: 11.75   Max: 31.9
Current: 16.5

11.75
31.9
P/B 5.24
GNC's P/B is ranked higher than
57% of the 589 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.32 vs. GNC: 5.24 )
GNC' s 10-Year P/B Range
Min: 2.17   Max: 6.81
Current: 5.24

2.17
6.81
P/S 1.59
GNC's P/S is ranked higher than
56% of the 589 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.53 vs. GNC: 1.59 )
GNC' s 10-Year P/S Range
Min: 0.92   Max: 2.3
Current: 1.59

0.92
2.3
PFCF 21.97
GNC's PFCF is ranked higher than
83% of the 589 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 37.57 vs. GNC: 21.97 )
GNC' s 10-Year PFCF Range
Min: 12.82   Max: 34.5
Current: 21.97

12.82
34.5
EV-to-EBIT 11.84
GNC's EV-to-EBIT is ranked higher than
86% of the 589 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 17.07 vs. GNC: 11.84 )
GNC' s 10-Year EV-to-EBIT Range
Min: 9.2   Max: 15.2
Current: 11.84

9.2
15.2
PEG 0.83
GNC's PEG is ranked higher than
97% of the 589 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 30.00 vs. GNC: 0.83 )
GNC' s 10-Year PEG Range
Min: 0   Max: 0.8
Current: 0.83

0
0.8
Current Ratio 3.46
GNC's Current Ratio is ranked higher than
97% of the 561 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.13 vs. GNC: 3.46 )
GNC' s 10-Year Current Ratio Range
Min: 2.88   Max: 3.91
Current: 3.46

2.88
3.91
Quick Ratio 1.23
GNC's Quick Ratio is ranked higher than
91% of the 561 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.63 vs. GNC: 1.23 )
GNC' s 10-Year Quick Ratio Range
Min: 0.93   Max: 1.85
Current: 1.23

0.93
1.85

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.42
GNC's Dividend Yield is ranked lower than
59% of the 473 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.80 vs. GNC: 1.42 )
GNC' s 10-Year Dividend Yield Range
Min: 0.27   Max: 1.9
Current: 1.42

0.27
1.9
Dividend Payout 0.23
GNC's Dividend Payout is ranked higher than
84% of the 589 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.61 vs. GNC: 0.23 )
GNC' s 10-Year Dividend Payout Range
Min: 0.18   Max: 0.3
Current: 0.23

0.18
0.3
Yield on cost (5-Year) 1.40
GNC's Yield on cost (5-Year) is ranked lower than
62% of the 478 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.02 vs. GNC: 1.40 )
GNC' s 10-Year Yield on cost (5-Year) Range
Min: 0.27   Max: 1.9
Current: 1.4

0.27
1.9
Share Buyback Rate -3.10
GNC's Share Buyback Rate is ranked higher than
64% of the 380 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.20 vs. GNC: -3.10 )
GNC' s 10-Year Share Buyback Rate Range
Min: 0   Max: -6.1
Current: -3.1

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.98
GNC's Price/Median PS Value is ranked higher than
86% of the 589 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.10 vs. GNC: 0.98 )
GNC' s 10-Year Price/Median PS Value Range
Min: 0.61   Max: 1.34
Current: 0.98

0.61
1.34
Earnings Yield (Greenblatt) 8.40
GNC's Earnings Yield (Greenblatt) is ranked higher than
85% of the 557 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.10 vs. GNC: 8.40 )
GNC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 6.6   Max: 10.8
Current: 8.4

6.6
10.8

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers
Compare: » details
Traded in other countries:IGN.Germany,
GNC Holdings Inc was founded in 1935. It is a specialty retailer of health and wellness products, including VMHS products, sports nutrition products, and diet products. The Company's business segments include: Retail, Franchising and Manufacturing/Wholesale. Its retail segment is engaged in sales of products to customers at its company-owned stores in the United States, Canada and Puerto Rico and through its websites, GNC.com, LuckyVitamin.com and DiscountSupplements.com. As of December 31, 2013, the Company operated 3,342 company-owned stores across all 50 states including the District of Columbia, Canada and Puerto Rico. Its franchise segment consists of its domestic and international franchise operations, and engaged in franchise activities mainly product sales to franchisees, royalties on franchise retail sales and franchise fees. As of December 31, 2013, there were 3,036 franchise stores operating, including 1,012 stores in the U.S. and 2,024 international franchise stores operating in over 50 international countries. Its franchise stores in the United States offer both its proprietary products and third-party products, with a product selection similar to that of its company-owned stores. Its international franchise stores are offered a more limited product selection than its franchise stores in the United States with the product selection heavily weighted toward proprietary products. Manufacturing/Wholesale segment consists of manufacturing operations in South Carolina and its wholesale sales business. This segment supplies its Retail and Franchise segments as well as various third parties with finished products. Its Manufacturing/Wholesale segment is engaged in sales of manufactured products to third parties, and the sale of its proprietary and third-party brand products to Rite Aid, Sam's Club, PetSmart and www.drugstore.com. Its wholesale operations are supported mainly by its Anderson, South Carolina distribution center. The Company's sales are in four major nutritional supplement categories: VMHS, sports nutrition, diet and other wellness. It offers high-quality nutritional supplements sold under its GNC proprietary brand names, including Mega Men, Ultra Mega, Total LeanTM, Pro Performance and Pro Performance AMP, Beyond Raw and under nationally recognized third-party brand names. Its online channels are, GNC.com, LuckyVitamin.com and DiscountSupplements.com. It competes with other specialty retailers, supermarkets, drugstores, mass merchants, multi-level marketing organizations, mail-order companies, other internet sites and a variety of other smaller participants. The Company is subject to also subject to regulation under various national, local and international laws.
» More Articles for GNC

Headlines

Articles On GuruFocus.com
Private Capital Reduces Holdings in Healthcare Stocks Dec 18 2014 
Why GNC Holdings Is a Good Buy Despite a Mixed Quarter Nov 30 2014 
Why Investors Should Expect a Turnaround at GNC Holdings Nov 18 2014 
These Health Retailers Are Enticing Long-Term Bets Aug 06 2014 
GNC Could Generate a 55% Return May 08 2014 
Herbalife and GNC Are Good Investments, Here’s Why Apr 17 2014 
Top 5 Stocks from TPG-Axon Mar 21 2013 
Billionaire Steven Cohen Vitamins Up with GNC Mar 04 2013 
Generac Holdings: Umbrellas Sell Better on and After Rainy Days Nov 28 2012 
President and CEO of GNC Holdings Inc. Joe Fortunato Sold 50,000 Shares Aug 08 2012 

More From Other Websites
GN ReSound: Performs strongly under the new contract in the VA Dec 15 2014
Get Fit, Feel Great With GNC PUREDGE™ Line of Whole-Food-Based Supplements Nov 24 2014
Get Fit, Feel Great With GNC PUREDGE™ Line of Whole-Food-Based Supplements Nov 24 2014
GN is renowned for its innovation capabilities - granted two 2015 CES Innovation Awards Honoree Nov 14 2014
GNC HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Nov 12 2014
Trian Fund lowers its position in Allegion Nov 11 2014
Trian Fund increases stake in PepsiCo Nov 10 2014
Goldman Sachs Upgrades GNC, Cuts Vitamin Shoppe Nov 07 2014
Goldman Sachs' Increase Price Targert on GNC from $44 to $49. Nov 07 2014
Will GNC (GNC) Stock Be Affected Today by This Analyst Upgrade? Nov 07 2014
GNC HOLDINGS, INC. Financials Nov 06 2014
GN Store Nord discontinues M&A opportunity following due diligence - initiation of new share buyback... Nov 05 2014
Announcement November 05, 2014 Nov 05 2014
10-Q for GNC Holdings, Inc. Nov 01 2014
GNC HOLDINGS, INC. Files SEC form 8-K/A, Results of Operations and Financial Condition Oct 31 2014
GNC beats 3Q profit forecasts Oct 30 2014
GNC beats 3Q profit forecasts Oct 30 2014
GNC Holdings Inc Earnings Call scheduled for 9:00 am ET today Oct 30 2014
GNC Holdings, Inc. Reports Third Quarter 2014 Results Oct 30 2014
GNC HOLDINGS, INC. Files SEC form 8-K, Results of Operations and Financial Condition Oct 30 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK